This Week in Pediatric Oncology
Science
August 05, 2011
Host Dr. Tim Cripe and co-host Maureen O’Brien discuss recent papers on immunotherapy and DNA sequencing studies revealing new potential targets in acute lymphoblastic leukemia (ALL).
1:45 min. Results on use of BiTE antibody (Bi-specific T-cell engaging) blinatumomab in adults with lymphoma and leukemia:
Exp Cell Res. 2011 May 15;317(9):1255-60. Epub 2011 Mar 16. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
J Clin Oncol. 2011 Jun 20;29(18):2493-8. Epub 2011 May 16. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Use of blinatumomab in pediatrics was recently reported in Germany, and an international phase I/II trial for pediatrics is due to begin accruing this year.
Leukemia. 2011 Jan;25(1):181-4. Epub 2010 Oct 14. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.
23:00 min. Recent findings from the TARGET Initiative (Therapeutically Applicable Research to Generate Effective Treatments) http://target.cancer.gov/
Through NIH's TARGET initiative, scientists sequenced 120 candidate genes in 187 high-risk childhood B-precursor acute lymphoblastic leukemias (HR B-ALL) and normal tissues and combined the results with data from previous studies using microarry and gene copy number studies. Sorting through this massive amount of information revealed a high frequency of recurrent genetic alterations in several specific cancer signaling pathways. The information appears to be useful to stratify these patients into subcategories, some of whom do much better than others. These data highlight potential new therapeutic targets in certain subsets of childhood ALL.
Blood. 2010 Dec 2;116(23):4874-84. Epub 2010 Aug 10. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome
Blood. 2011 Jun 16. [Epub ahead of print] Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: a report from theChildren's Oncology Group
Please send all questions or comments to twipo@solvingkidscancer.org
TWIPO #52 ~ Interview with Dr. James Geller
TWIPO #51 ~ Interview with Dr. Gregory Armstrong
TWIPO #50 ~ Interview With Dr. Jonathan Finlay
TWIPO #49 ~ Interview With Dr. Robin Norris
TWIPO #48 ~ Interview With Dr. Michael D. Hogarty
TWIPO #47 ~ Interview With Dr. Hiro Shimada
TWIPO #46 ~ ANR Recap: Interview With Dr. Sue Cohn
TWIPO #45 ~ Immunotherapy Vaccine for Immunotherapy Vaccine for High-Grade Gliomas
TWIPO #44 ~ ANR Recap: Interview With Professor Michelle Haber and Professor Andrew Pearson
TWIPO #43 ~ Langerhans cell histiocytosis : Interview With Carl E. Allen
TWIPO #42 ~ Advances in Neuroblastoma Research Meeting Recap: Interview With Frank Berthold
TWIPO #41 ~ Advances in Neuroblastoma Research Meeting Recap: Advances in Understanding MIBG Therapy
TWIPO #40 ~ Advances in Neuroblastoma Research Meeting Recap: Advances in Understanding MYCN
TWIPO #39 ~ Declining Childhood Cancer Mortality & CAR123 T-cells
TWIPO #38 ~ Interview with John Goldberg, MD, on Phase I Clinical Trials
TWIPO #37 ~ Interview with Patrick Brown, MD, on Infant Leukemia
TWIPO #36 ~ Interview With Kathleen Neville, MD, on Pediatric Drug Development
TWIPO #35 ~ Interview With Robert Johnson, PhD
TWIPO #34 ~Interview With Dr. Nancy Ratner
TWIPO #33 ~Effective Advocacy with Gavin Lindberg
Create your
podcast in
minutes
It is Free
The Psychic Elephant Radio Podcast
DNA Today: A Genetics Podcast
Museum of the Missing
Sasquatch Chronicles
Hidden Brain